FBRX News and Press, Forte Biosciences Inc. From 05/03/21

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021. Conference Call and Webcast Information Forte management will host a con...

Forte Biosciences is developing a first-in-class drug for eczema, which affects over 16M patients in the US. Phase 1 data for Forte's lead asset, FB-401, has shown exceptional safety and supported a phase 2 trial that is expected to report data in mid-2021. This has created a comp...

The company’s key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa. FB-401 is being developed in mild to moderate atopic dermatitis and has FDA Fast track designation based on Phase ...

Two new breakout stocks for Week 13 of 2021 with better than 10% short-term upside potential. This past week one selection gained over 10% with KIRK +16.2% in the early part of the week before giving back all its gains and more. 2021 MDA minimal portfolio returns are up +10.3% YTD...

Citi analyst Mohit Bansal has initiated Forte Biosciences (FBRX) with a buy rating and a $75 price target.Given yesterday's closing price of $28.92, that represents an upside of ~159%.Bansal's rating is based on the company's lead asset, FB-401, which he believes can become the standard of ca...

Aspira Women's Health (AWH) has extended the post-market gains with a ~12.2% rise in the pre-market as analysts weigh in on its new agreement to develop an early detection test for ovarian cancer.“We support the notion of the team taking another big swing and working to ...

Forte Biosciences (FBRX): Q4 GAAP EPS of -$0.37.Cash and cash equivalents of ~$58.8M.Press Release For further details see: Forte Biosciences reports Q4 results

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021. “Forte made significant progress in the fourth quarter o...

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021. Conference Call and Webcast Information Forte management wi...

Forte Biosciences (FBRX) jumped jumped up 10% after a Chardan report said the stock may be worth almost $840 a share.Developing story ... For further details see: Forte Biosciences spikes as Chardan sees value of more than $800/share